Stockreport

LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade) [Seeking Alpha]

LENZ Therapeutics, Inc.  (LENZ) 
PDF Q4 2025 revenue was $1.6M on 20,000 prescriptions, with high S,G&A costs ($39.6M) and a net loss of $35.9M. LENZ faces significant risks: high cash burn, shareholder [Read more]